BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37463943)

  • 1. Mechanism and therapeutic implications of pomalidomide-induced immune surface marker upregulation in EBV-positive lymphomas.
    Jaeger HK; Davis DA; Nair A; Shrestha P; Stream A; Yaparla A; Yarchoan R
    Sci Rep; 2023 Jul; 13(1):11596. PubMed ID: 37463943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells.
    Davis DA; Shrestha P; Aisabor AI; Stream A; Galli V; Pise-Masison CA; Tagawa T; Ziegelbauer JM; Franchini G; Yarchoan R
    Oncoimmunology; 2019; 8(2):e1546544. PubMed ID: 30713808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas.
    Hatton O; Phillips LK; Vaysberg M; Hurwich J; Krams SM; Martinez OM
    J Biol Chem; 2011 Oct; 286(43):37368-78. PubMed ID: 21908615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
    Shrestha P; Davis DA; Jaeger HK; Stream A; Aisabor AI; Yarchoan R
    PLoS Pathog; 2021 Jan; 17(1):e1009091. PubMed ID: 33411730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells.
    Liu S; Li H; Chen L; Yang L; Li L; Tao Y; Li W; Li Z; Liu H; Tang M; Bode AM; Dong Z; Cao Y
    Carcinogenesis; 2013 Mar; 34(3):627-37. PubMed ID: 23180656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional role of phosphatidylinositol 3-kinase/Akt pathway on cell growth and lytic cycle of Epstein-Barr virus in the Burkitt's lymphoma cell line, P3HR-1.
    Mori T; Sairenji T
    Virus Genes; 2006 Jun; 32(3):327-34. PubMed ID: 16732486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.
    Hatton O; Lambert SL; Phillips LK; Vaysberg M; Natkunam Y; Esquivel CO; Krams SM; Martinez OM
    Am J Transplant; 2013 Apr; 13(4):883-890. PubMed ID: 23398911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus upregulates phosphorylated heat shock protein 27 kDa in carcinoma cells using the phosphoinositide 3-kinase/Akt pathway.
    Fukagawa Y; Nishikawa J; Kuramitsu Y; Iwakiri D; Takada K; Imai S; Satake M; Okamoto T; Fujimoto M; Okita K; Nakamura K; Sakaida I
    Electrophoresis; 2008 Aug; 29(15):3192-200. PubMed ID: 18604870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell cycle arrest induced by engagement of B7-H4 on Epstein-Barr virus-positive B-cell lymphoma cell lines.
    Park GB; Song H; Kim YS; Sung M; Ryu JW; Lee HK; Cho DH; Kim D; Lee WJ; Hur DY
    Immunology; 2009 Nov; 128(3):360-8. PubMed ID: 20067536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. l-Asparaginase synergizes with etoposide via the PI3K/Akt/mTOR pathway in Epstein-Barr virus-positive Burkitt lymphoma.
    Sang W; Tu D; Zhang M; Qin Y; Yin W; Song X; Sun C; Yan D; Wang X; Zeng L; Li Z; Xu K; Xu L
    J Biochem Mol Toxicol; 2022 Aug; 36(8):e23117. PubMed ID: 35757978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting.
    Martorelli D; Muraro E; Mastorci K; Dal Col J; Faè DA; Furlan C; Giagulli C; Caccuri F; Rusnati M; Fiorentini S; Carbone A; Caruso A; Dolcetti R
    Int J Cancer; 2015 Sep; 137(6):1374-85. PubMed ID: 25704763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
    Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
    Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 upregulation by lytic induction of Epstein-Barr Virus.
    Yanagi Y; Hara Y; Mabuchi S; Watanabe T; Sato Y; Kimura H; Murata T
    Virology; 2022 Mar; 568():31-40. PubMed ID: 35093708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr Virus Infection of Cell Lines Derived from Diffuse Large B-Cell Lymphomas Alters MicroRNA Loading of the Ago2 Complex.
    Ayoubian H; Ludwig N; Fehlmann T; Menegatti J; Gröger L; Anastasiadou E; Trivedi P; Keller A; Meese E; Grässer FA
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
    Vargas-Ayala RC; Jay A; Manara F; Maroui MA; Hernandez-Vargas H; Diederichs A; Robitaille A; Sirand C; Ceraolo MG; Romero-Medina MC; Cros MP; Cuenin C; Durand G; Le Calvez-Kelm F; Mundo L; Leoncini L; Manet E; Herceg Z; Gruffat H; Accardi R
    J Virol; 2019 Jul; 93(13):. PubMed ID: 30996097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules.
    Wu Y; Shrestha P; Heape NM; Yarchoan R
    J Transl Med; 2022 May; 20(1):217. PubMed ID: 35562811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin-9 Facilitates Epstein-Barr Virus Latent Infection and Lymphomagenesis in Human B Cells.
    Xu JX; Zhang R; Huang DJ; Tang Y; Ping LQ; Huang BJ; Huang HQ; Busson P; Li J
    Microbiol Spectr; 2023 Feb; 11(1):e0493222. PubMed ID: 36622166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EBV-Upregulated B7-H3 Inhibits NK cell-Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression.
    Chen H; Duan X; Deng X; Huang Y; Zhou X; Zhang S; Zhang X; Liu P; Yang C; Liu G; Ren Q; Xiong Y; Zhu B; Zhang J; Xiang T
    Cancer Immunol Res; 2023 Jun; 11(6):830-846. PubMed ID: 36996321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells.
    Westhoff Smith D; Chakravorty A; Hayes M; Hammerschmidt W; Sugden B
    mBio; 2021 Dec; 12(6):e0224321. PubMed ID: 34781735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
    Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
    Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.